- Lonza has announced an extended collaboration with a major biopharma partner to expand commercial-scale ADC manufacturing through the construction of a new bioconjugation suite.
- The new facility at Visp, Switzerland, will cover 800m² and is expected to be operational by 2027, creating around 100 new jobs.

Lonza, a global contract development and manufacturing organisation (CDMO), has announced the extension of its collaboration with a major biopharmaceutical partner for the large-scale production of antibody-drug conjugates (ADCs). The agreement will include the construction of a new bioconjugation suite at Lonza’s Ibex® Biopark in Visp, Switzerland, furthering their existing partnership in ADC manufacturing.
The new suite will occupy approximately 800 square metres and is expected to be operational by 2027. It will support commercial manufacturing, including handling highly potent compounds and employing 100 additional staff. The facility is designed to streamline the manufacture of a new ADC therapy targeting difficult-to-treat cancers.
Alongside the new bioconjugation suite, Lonza will continue to provide monoclonal antibody (mAb) manufacturing services for the ADC at its facility in Porriño, Spain. The expanded agreement allows Lonza to consolidate its role in the end-to-end production process, from antibody production to drug-linker conjugation and drug product filling.
Christian Morello, Vice President, Head of Bioconjugates at Lonza, commented: “The relationship with our valued partner has evolved over the years to incorporate all stages of bioconjugate manufacturing and commercialisation. Offering end-to-end ADC manufacturing services eliminates supply chain complexities and streamlines product delivery at scale.”
Read about ADC Antibody Drug Conjugates CDMO Market 2024 Here.